FBXO11突变频发凸显BCL6作为伯基特淋巴瘤治疗靶点
本研究揭示FBXO11突变在23%的伯基特淋巴瘤患者中存在,该突变损害BCL6降解并稳定BCL6水平。小鼠实验表明FBXO11是B细胞淋巴瘤的单倍剂量不足抑癌基因,与致癌MYC协同加速淋巴瘤发生。靶向BCL6的降解剂或抑制剂可部分抑制淋巴瘤生长,联合MYC抑制效果更佳,提示BCL6和MYC是潜在治疗靶点。
要点
- FBXO11突变见于23%的伯基特淋巴瘤患者,导致BCL6降解受损。
- FBXO11是B细胞淋巴瘤的单倍剂量不足抑癌基因,与MYC协同促瘤。
- 靶向BCL6联合MYC抑制可增强抗淋巴瘤效果。
核心结论
- FBXO11突变在伯基特淋巴瘤中频发,功能上导致BCL6稳定,支持BCL6作为治疗靶点。
- 靶向BCL6的降解剂或抑制剂联合MYC抑制可能成为伯基特淋巴瘤的靶向治疗策略。
研究设计与样本
- 研究分析了伯基特淋巴瘤患者样本中FBXO11突变频率,并在人伯基特淋巴瘤细胞系和小鼠模型中验证功能。
- 使用条件性敲除FBXO11基因1或2个拷贝的小鼠,结合致癌MYC,观察淋巴瘤发生。
主要发现
- FBXO11突变在23%的伯基特淋巴瘤患者中发现。
- FBXO11突变损害BCL6降解,FBXO11蛋白缺失完全稳定人伯基特淋巴瘤细胞系中BCL6水平。
- 小鼠中条件性删除FBXO11基因1或2个拷贝与致癌MYC协同加速B细胞淋巴瘤发生。
- 在野生型和FBXO11缺陷的伯基特淋巴瘤小鼠及人细胞系中,靶向BCL6的降解剂或抑制剂部分抑制淋巴瘤体外和体内生长。
- Omomyc迷你蛋白抑制MYC阻断细胞增殖并增加凋亡,联合BCL6靶向效果进一步增强。
关键数值与推荐
- FBXO11突变频率为23%(伯基特淋巴瘤患者)。
- FBXO11条件性删除1或2个拷贝与MYC协同加速B细胞淋巴瘤发生。
- BCL6靶向降解剂或抑制剂部分抑制淋巴瘤生长(体外和体内)。
- Omomyc抑制MYC阻断增殖并增加凋亡,联合BCL6靶向效果进一步增强。
临床怎么用
- 伯基特淋巴瘤中FBXO11突变状态可能提示BCL6蛋白稳定性,支持BCL6靶向治疗探索。
- BCL6降解剂或抑制剂联合MYC抑制(如Omomyc)可能作为伯基特淋巴瘤的潜在靶向策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The expression of BCL6 in B-cell lymphoma can be deregulated by chromosomal translocations, somatic mutations in the promoter regulatory regions, or reduced proteasome-mediated degradation. FBXO11 was recently identified as a ubiquitin ligase that is involved in the degradation of BCL6, and it is frequently inactivated in lymphoma or other tumors. Here, we show that FBXO11 mutations are found in 23% of patients with Burkitt lymphoma (BL). FBXO11 mutations impaired BCL6 degradation, and the deletion of FBXO11 protein completely stabilized BCL6 levels in human BL cell lines. Conditional deletion of 1 or 2 copies of the FBXO11 gene in mice cooperated with oncogenic MYC and accelerated B-cell lymphoma onset, providing experimental evidence that FBXO11 is a haploinsufficient oncosuppressor in B-cell lymphoma. In wild-type and FBXO11-deficient BL mouse and human cell lines, targeting BCL6 via specific degraders or inhibitors partially impaired lymphoma growth in vitro and in vivo. Inhibition of MYC by the Omomyc mini-protein blocked cell proliferation and increased apoptosis, effects further increased by combined BCL6 targeting. Thus, by validating the functional role of FBXO11 mutations in BL, we further highlight the key role of BCL6 in BL biology and provide evidence that innovative therapeutic approaches, such as BCL6 degraders and direct MYC inhibition, could be exploited as a targeted therapy for BL.
引用
- Pighi C, Cheong TC, Compagno M, et al. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Adv. 2021. PMID: 34625792. doi:10.1182/bloodadvances.2021005682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。